EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning

References

• Rickinson A B, Lee S P, Steven N M. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1996; 8: 492–497
   PubMed Web of Science ®Google Scholar
• Wilkinson A H, Smith J L, Hunsicker L G, Tobacman J, Kapelanski D P, Johnson M, et al. Increased frequency of post-transplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47: 293–296
   PubMed Web of Science ®Google Scholar
• Micallef I N, Chhanabhai M, Gascoyne R D, Shepherd J D, Fung H C, Nantel S H, et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998; 22: 981–987
   PubMed Web of Science ®Google Scholar
• Antin J H, Bierer B E, Smith B R, Ferrara J, Guinan E C, Sieff C, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139–2149
   PubMed Web of Science ®Google Scholar
• Hale G, Zhang M J, Bunjes D, Prentice H G, Spence D, Horowitz M M, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581–4590
   PubMed Web of Science ®Google Scholar
• Gerritsen E J, Stam E D, Hermans J, van den B H, Haraldsson A, van Tol M J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996; 18: 377–382
   PubMed Web of Science ®Google Scholar
• Barker J N, Martin P L, Coad J E, DeFor T, Trigg M E, Kurtzberg J, et al. Low incidence of Epstein-Barr virus-associated post-transplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001; 7: 395–399
   PubMed Web of Science ®Google Scholar
• Brunstein C G, Weisdorf D J, Defor T, Barker J N, Tolar J, van Burik J A, et al. Marked increased risk of epstein-barr virus-related complications with the addition of anti-thymocyte globulin to a non-myeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874–2880
   PubMed Web of Science ®Google Scholar
• Rooney C M, Loftin S K, Holladay M S, Brenner M K, Krance R A, Heslop H E. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98–103
   PubMed Web of Science ®Google Scholar
• van Esser J WJ, van der Holt B, Meijer E, Niesters H GM, Trenschel R, Thijsen S FT, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972–978
   PubMed Web of Science ®Google Scholar
• Wagner H J, Cheng Y C, Huls M H, Gee A P, Kuehnle I, Krance R A, et al. Prompt versus pre-emptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979–3981
   PubMed Web of Science ®Google Scholar
• Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U, et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005; 129: 229–239
   PubMed Web of Science ®Google Scholar
• Meij P, van Esser J WJ, Niesters H GM, van Baarle D, Miedema F, Blake N, et al. Impaired recovery of Epstein-Barr virus (EBV)—specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290–4297
   PubMed Web of Science ®Google Scholar
• Nalesnik M A. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 1998; 20: 325–342
   PubMed Web of Science ®Google Scholar
• O'Riordan J M, Molloy K, O'Briain D S, Corbally N, Devaney D, McShane D, et al. Localized, late-onset, high-grade lymphoma following bone marrow transplantation: response to combination chemotherapy. Br J Haematol 1994; 86: 183–186
   PubMed Web of Science ®Google Scholar
• Kuehnle I, Huls M H, Liu Z, Semmelmann M, Krance R A, Brenner M K, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502–1505
   PubMed Web of Science ®Google Scholar
• Faye A, Quartier P, Reguerre Y, Lutz P, Carret A S, Dehee A, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112–118
   PubMed Web of Science ®Google Scholar
• van Esser J WJ, Niesters H GM, van der Holt B, Meijer E, Osterhaus A DME, Gratama J W, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364–4369
   PubMed Web of Science ®Google Scholar
• Gruhn B, Meerbach A, Hafer R, Zell R, Wutzler P, Zintl F. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 1023–1025
   PubMed Web of Science ®Google Scholar
• Papadopoulos E B, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi M H, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185–1191
   PubMed Web of Science ®Google Scholar
• Lucas K G, Burton R L, Zimmerman S E, Wang J, Cornetta K G, Robertson K A, et al. Epstein-Barr Virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654–3661
   PubMed Web of Science ®Google Scholar
• O'Reilly R J, Small T N, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157: 195–216
   PubMed Web of Science ®Google Scholar
• Rooney C M, Smith C A, Ng C YC, Loftin S K, Sixbey J W, Gan Y, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549–1555
   PubMed Web of Science ®Google Scholar
• Gustafsson A, Levitsky V, Zou J Z, Frisan T, Dalianis T, Ljungman P, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807–814
   PubMed Web of Science ®Google Scholar
• Rooney C M, Smith C A, Ng C Y, Loftin S, Li C, Krance R A, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9–13
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Sandmaier B M, Maloney D G, Maris M, McSweeney P A, Woolfrey A, et al. Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. J Clin Immunol 2002; 22: 70–74
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Thomson K, Morris E, Kottaridis P D, Peggs K S. Reduced intensity transplantation: where are we now?. Hematol J 2004; 5(Suppl 3)S34–S38
   PubMedGoogle Scholar
• Spitzer T R. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 2000; 5: 215–223
   PubMedGoogle Scholar
• Khouri I F, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763
   PubMed Web of Science ®Google Scholar
• Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241
   PubMed Web of Science ®Google Scholar
• Sykes M, Preffer F, McAfee S, Saidman S L, Weymouth D, Andrews D M, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755–1759
   PubMed Web of Science ®Google Scholar
• Cooper N, Rao K, Gilmour K, Hadad L, Adams S, Cale C, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006; 107: 1233–1236
   PubMed Web of Science ®Google Scholar
• Rao K, Amrolia P J, Jones A, Cale C M, Naik P, King D, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879–885
   PubMed Web of Science ®Google Scholar
• Morris E C, Mackinnon S. Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma. Best Pract Res Clin Haematol 2005; 18: 129–142
   PubMed Web of Science ®Google Scholar
• Anagnastopoulos A, Aleman A, Giralt S. Nonmyeloablative reduced-intensity transplantation in multiple myeloma. Semin Oncol 2004; 31: 33–36
   PubMed Web of Science ®Google Scholar
• Burroughs L, Storb R. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. Curr Opin Hematol 2005; 12: 45–54
   PubMed Web of Science ®Google Scholar
• Buffart T E, Janssen J J, Huijgens P C. Reduced-intensity conditioning regimens in malignant haematological diseases. Neth J Med 2005; 63: 43–51
   PubMed Web of Science ®Google Scholar
• Gibson J, Ho P J, Joshua D. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic. Transplant Proc 2004; 36: 2501–2503
   PubMed Web of Science ®Google Scholar
• Niederweiser D, Gentilini C, Hegenbart U, Lange T, Becker C, Wang S, et al. Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. Crit Rev Oncol Hematol 2005; 56: 275–281
   PubMed Web of Science ®Google Scholar
• Blaise D, Mohty M, Faucher C, Olive D, Chabannon C. Current update on reduced intensity regimens for allogeneic stem cell transplantation. Haematol 2005; 10(Suppl 1)64–65
   Google Scholar
• Resnick I B, Shapira M Y, Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transplant Immunol 2005; 14: 207–219
   PubMed Web of Science ®Google Scholar
• Haddad N, Rowe J M. Current indications for reduced-intensity allogeneic stem cell transplantation. Best Pract Res Clin Haematol 2004; 17: 377–386
   PubMed Web of Science ®Google Scholar
• Satwani P, Harrison L, Morris E, Del Toro G, Cairo M S. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. BBMT 2005; 11: 403–422
   Google Scholar
• Banna G L, Aversa S, Sileni V C, Favaretto A, Ghiotto C, Monfardini S, et al. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol 2004; 51: 171–189
   PubMed Web of Science ®Google Scholar
• Shroff R, Trompeter R, Cubitt D, Thaker U, Rees L. Epstein-Barr virus monitoring in paediatric renal transplant recipients. Pediatr Nephrol 2002; 17: 770–775
   PubMed Web of Science ®Google Scholar
• Nalesnik M A. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 1998; 20: 325–342
   PubMed Web of Science ®Google Scholar
• Peggs K S, Banerjee L, Thomson K, Mackinnon S. Post-transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion. Bone Marrow Transplant 2003; 31: 725–726
   PubMed Web of Science ®Google Scholar
• Ho A Y, Adams S, Shaikh H, Pagliuca A, Devereux S, Mufti G J. Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. Bone Marrow Transplant 2002; 29: 867–869
   PubMed Web of Science ®Google Scholar
• Snyder M J, Stenzel T T, Buckley P J, Lagoo A S, Rizzieri D A, Gasparetto C, et al. Post-transplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004; 28: 794–800
   PubMed Web of Science ®Google Scholar
• Milpied N, Coste-Burel M, Accard F, Moreau A, Moreau P, Garand R, et al. Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 23: 629–630
   PubMed Web of Science ®Google Scholar
• Juvonen E, Aalto S M, Tarkkanen J, Volin L, Mattila P S, Knuutila S, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32: 97–102
   PubMed Web of Science ®Google Scholar
• Gong J Z, Bayerl M G, Sandhaus L M, Sebastian S, Rehder C W, Routbort M, et al. Post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol 2006; 30: 328–336
   PubMed Web of Science ®Google Scholar
• Lange A, Klimczak A, Dlubek D, Dybko J. B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen. Transplant Proc 2003; 35: 3093–3095
   PubMed Web of Science ®Google Scholar
• Saito T, Kanda Y, Nakai K, Kim S W, Arima F, Kami M, et al. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial cosmparison with conventional myeloablative transplantation. Bone Marrow Transplant 2003; 32: 601–608
   PubMed Web of Science ®Google Scholar
• Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V, et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005; 33: 920–927
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R, Kottaridis P D, Peggs K, O'Gorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357–4363
   PubMed Web of Science ®Google Scholar
• Morris E C, Rebello P, Thomson K J, Peggs K S, Kyriakou C, Goldstone A H, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404–406
   PubMed Web of Science ®Google Scholar
• Lamba R, Carrum G, Myers G D, Bollard C M, Krance R A, Heslop H E, et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant 2005; 36: 797–802
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mautner V, Osman H, Collingham K E, Fegan C D, Klapper P E, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100: 1619–1627
   PubMed Web of Science ®Google Scholar
• Avivi I, Chakrabarti S, Milligan D W, Waldmann H, Hale G, Osman H, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 2004; 10: 186–194
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Milligan D W, Pillay D, Mackinnon S, Holder K, Kaur N, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003; 102: 839–842
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Avivi I, Mackinnon S, Ward K, Kottaridis P D, Osman H, et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002; 119: 1125–1132
   PubMed Web of Science ®Google Scholar